Uptake and spending on biosimilar infliximab and etanercept after new start and switching policies in Canada: An interrupted time series analysis.
Alison R McCleanLucy ChengNick BansbackFiona ClementMina TadrousMark HarrisonMichael R LawPublished in: Arthritis care & research (2023)
We found that mandatory switching policies were much more effective than new starting policies for increasing the use of biosimilar medications.